US Edition
Applications Open Soon for Psychedelic Healing Centers in Denver
UNITED STATES, JUN 23 – Compass Pathways' synthetic psilocybin drug COMP360 showed a clinically meaningful 3.6-point improvement in depression severity six weeks after a single dose in treatment-resistant patients.
- On June 25, 2025, researchers released results from a phase 2 study demonstrating that a single 25-mg dose of psilocybin, accompanied by therapeutic support, significantly alleviated emotional distress in individuals with cancer, with benefits lasting more than two years.
- This trial builds on prior studies indicating psilocybin’s antidepressant effects and aims to expand treatment with larger samples and multiple doses.
- The published trial involved 28 cancer patients receiving a single 25 mg dose of psilocybin combined with therapy, showing effects lasting over two years.
- Compass Pathways and experts warn that upfront costs of psychedelic-assisted therapies remain high but can be reduced, for example, through group therapy sessions.
- State-Level legal changes in Oregon, Colorado, and New Mexico reflect growing acceptance, while federal approval remains elusive and treatment affordability is a key challenge.
14 Articles
14 Articles
Applications open soon for psychedelic healing centers in Denver
DENVER (KDVR) — A new era in mental health care begins Thursday as Denver is expected to open its application portal for psychedelic healing centers, part of Colorado’s regulated natural medicine program. The move follows the passage of state legislation establishing a framework for psilocybin therapy — a psychedelic compound found in certain mushrooms — for approved mental health treatment. Licensed facilities in cities like Golden are preparin…
MedPage Today
Anti-Aging, Acupuncture and Health NewsPsilocybin Win in Depression; Top Industries for Mental Distress; Heatwaves and Mood
(MedPage Today) -- A single dose of synthetic psilocybin significantly reduced symptoms of treatment-resistant depression in a 6-week phase III trial, said developer Compass Pathways. In an opinion piece, Allen Frances, MD, chair of the DSM-IV...
Phase 3 Trial of Psilocybin for Depression Reportedly Shows Great Promise
An ongoing advanced clinical trial of psilocybin as a depression treatment reportedly shows great promise. Caution is required when the data have not yet been published. But if confirmed, this could be a landmark in the psychedelic drug’s journey toward federal approval as a medical treatment in the United States. On June 23, biotechnology company Compass Pathways announced it had reached the primary endpoint of its Phase 3 clinical trial studyi…
How Psilocybin May Provide Relief for Postpartum Depression
Early research has suggested psilocybin, the active ingredient in magic mushrooms, may be effective at treating clinical depression and PTSD. Now, it is being studied as a potential new therapy for postpartum depression, a serious conditions which affects one in 7 new mothers. Maria Shriver reports for TODAY.
Coverage Details
Bias Distribution
- 43% of the sources lean Left, 43% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
